From the Canadian Journal of Chemical Engineering via the Wiley Online Library comes an article authored by Dark Horse Senior Consultant Sara Mills in tandem with Elizabeth Csaszar and Peter Zandstra.
Access the full article, “Process evolution in cell and …
By Anthony Davies, Rob Allen, and Ian Pardo
We at Dark Horse are intrigued by the Medicines and Healthcare products Regulatory Agency (MHRA)’s latest: the advent of an “innovation passport” to create an accelerated route—or at the very least, clear …
Are you signed up to receive our quarterly newsletter? If not, sign up here.
This page provides you with a complete list of our past issues.
In honor of the inaugural issue of The Quarter Horse, Katy Spink, Dark Horse’s COO, sat down with Donald Fink, Master Practice Expert in Regulatory, to discuss the patterns of C> regulatory rejections/delays during the past 15 months.
Katy: We’ve …
Principal Nate Manley was interviewed by Insights Bio this month for a Cell and Gene Therapy Insights raw and starting materials spotlight article entitled, “Emerging trends in control and regulation of immunotherapy cellular starting materials.”
Read the full article, including …
published 16 Mar 2021 at written by Amanda Micklusreproduced with permission
PDF available for download, here
Regenerative medicines have made significant advancements in …
Walnut Creek, CA—Dark Horse Consulting (DHC) today announces the make-up of its Board of Directors.
Dark Horse Consulting, the rapidly growing global consulting practice specializing exclusively in cell and gene therapies, understands the challenges specific to C> sponsors, tool providers, …
Happy Eve of Not #JPMorgan: here are my in-no-particular-order Top 10 predictions for the year in cell and gene therapy, not so much as a Nostradamus impression, but hopefully more a provocation of thought…
#1 The investment and acquisition arms…Walnut Creek, CA—Dark Horse Consulting Group (DHC), the only global consulting practice specializing exclusively in cell and gene therapies, announces renowned FDA expert Donald Fink, Ph.D. as their latest hire.
After 27 years spent at the United States Food and …
by Katy Spink, DHC’s COO and Managing PartnerAddendum below* added on 1/5/2021
The end of 2020 didn’t arrive a moment too soon for most people I know, and the field of cell and gene therapy at large must have felt …
